Acceleron Pharma Inc. | Ownership
Companies that own Acceleron Pharma Inc.
T. Rowe Price Associates, Inc.
4,290,792
9.33%
662,570
0.03%
06/30/2018
Fidelity Management & Research Co.
3,628,550
7.89%
39,739
0.02%
06/30/2018
BlackRock Fund Advisors
2,936,201
6.38%
161,656
0.01%
06/30/2018
The Vanguard Group, Inc.
2,504,683
5.45%
71,436
0%
06/30/2018
SSgA Funds Management, Inc.
1,533,710
3.33%
68,721
0.01%
06/30/2018
Perceptive Advisors LLC
1,528,205
3.32%
11,946
1.88%
06/30/2018
Farallon Capital Management LLC
1,401,000
3.05%
0
0.5%
06/30/2018
Fidelity (Canada) Asset Management ULC
1,305,932
2.84%
603,464
0.11%
06/30/2018
Henderson Global Investors Ltd.
1,233,207
2.68%
1,233,207
0.03%
06/30/2018
Deerfield Management Company LP
1,126,800
2.45%
511,800
1.74%
06/30/2018
| Address |
128 Sidney Street
Cambridge Massachusetts 02139
United States
|
|
Employees
|
- |
| Website |
http://www.acceleronpharma.com |
| Updated |
07/08/2019 |
| Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. |
